In JAMA Neurology, the group challenged the "movement" to define Alzheimer's disease as a "purely biological entity based on biomarker findings." ...
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback